29 March 2023 in In vitro models
Purpose Ischemic brain injury occurs when there is reduced or complete disruption of blood flow to a brain region, such as in stroke or severe traumatic brain injury. Even short interruptions can lead to devastating effects including excitotoxicity and widespread cell death. Despite many decades of research, there are still very few therapeutic options for patients suffering from brain ischemia. Methods We developed an in vitro brain ischemia model using our previously established 3D spheroids derived from primary postnatal rat cortex. These spheroids provide an in vivo-relevant model containing a similar cellular composition to the native cortex and a cell-synthesized extracellular matrix. This model is cost-effective, highly reproducible, and can be produced in a high-throughput manner, making it an ideal candidate for screening potential therapeutics. To study the cellular and molecular mechanisms of stroke in this model, spheroids were deprived of glucose, oxygen, or both oxygen and glucose for 24 h. Results Both oxygen and oxygen-glucose deprived spheroids demonstrated many of the hallmarks of ischemic brain injury, including a decrease in metabolism, an increase in neural dysfunction, breakdown in the neurovascular unit, and an increase in reactive astrocytes. Pretreatment of spheroids with the antioxidant agent N-acetylcysteine (NAC) mitigated the decrease in ATP after oxygen–glucose deprivation, was partially neuroprotective, and enhanced the expression of laminin. Conclusion This 3D cortical spheroid model provides a platform for studying ischemic injury and has the potential for screening therapeutics.
16 October 2021 in bioRxiv
Stroke is a devastating neurological disorder and a leading cause of death and long-term disability. Despite many decades of research, there are still very few therapeutic options for patients suffering from stroke or its consequences. This is partially due to the limitations of current research models, including traditional in vitro models which lack the three-dimensional (3D) architecture and cellular make-up of the in vivo brain. 3D spheroids derived from primary postnatal rat cortex provide an in vivo -relevant model containing a similar cellular composition to the native cortex and a cell-synthesized extracellular matrix. These spheroids are costeffective, highly reproducible, and can be produced in a high-throughput manner, making this model an ideal candidate for screening potential therapeutics. To study the cellular and molecular mechanisms of stroke in this model, spheroids were deprived of glucose, oxygen, or both oxygen and glucose for 24 hours. Both oxygen and oxygen-glucose deprived spheroids demonstrated many of the hallmarks of stroke, including a decrease in metabolism, an increase in neural dysfunction, and an increase in reactive astrocytes. Pretreatment of spheroids with the antioxidant agent N-acetylcysteine (NAC) mitigated the decrease in ATP seen after 24 hours of oxygen-glucose deprivation. Together, these results show the utility of our 3D cortical spheroid model for studying ischemic injury and its potential for screening stroke therapeutics. Significance Statement: Those who survive after suffering a stroke often have long-term cognitive or physical disabilities. There is currently only one available therapeutic, tissue plasminogen activator (tPA), and it must be administered within a few hours after the onset of stroke. As stroke prevalence increases with our aging population, there is a growing need for therapies to mitigate or reverse the resulting brain damage. Three-dimensional (3D) culture systems have the potential to screen novel therapeutics more reliably than traditional in vitro models. Here we present a novel 3D cortical spheroid ischemia model which replicates many of the characteristics of stroke and has the potential to be an effective tool in therapeutic development.
11 September 2026 in Science Advances
Long-term humoral immunity relies on long-lived plasma cells in the bone marrow (BM). However, the processes governing plasma cell transport, positioning, and longevity within the BM niche remain poorly understood, especially in humans. Most existing knowledge comes from mouse studies or limited human-based models, which makes translating findings to human biology challenging. Here, we introduce a physiologically relevant human bone marrow-on-a-chip (hBMOC) model to investigate the behavior and interactions of human immune organoid-derived antibody-secreting cells (ASCs) within the human BM microenvironment. The hBMOC model is microvascular and perfusable and incorporates both endosteal and perivascular niches. We demonstrate that human ASCs migrate through blood vessels, accumulating and clustering in perivascular areas where they are closely associated with critical survival factors. In addition, we found that the presence of the endosteal niche substantially affects human ASC survival, movement, and retention, underscoring the dynamic interactions among human BM subniches that regulate ASC activity. We observed that a subset of human ASCs exhibits a dynamic stop-and-go migration pattern partially regulated by CXCR4-CXCL12 signaling. These findings provide direct insight into human ASC biology that has remained poorly defined, including their niche-specific localization, survival, and migratory dynamics within a three-dimensional human bone marrow microenvironment. Our results emphasize the distinct and cooperative roles of perivascular and endosteal compartments in supporting human ASC fate, offering previously inaccessible mechanistic insights into how human BM niches regulate plasma cells. This work lays the groundwork for studying plasma cell aging, vaccine durability, and disease-related dysfunction in human ASC maintenance and persistence.